nat cell biol 2017 cell lines  (ATCC)

Journal: bioRxiv

Article Title: The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in HCT116 colon cancer cells

doi: 10.1101/2023.03.17.533075

Figure Lengend Snippet: A . Immunofluorescence experiments performed on HCT116 cells treated, or not, with oxaliplatin (0.5 μM) monitoring g-H2AX (yellow). DAPI (blue) was used to stain DNA and the nuclei. Quantification of the staining is shown on the right side and is represented as the corrected nuclear fluorescence. Data are represented as the mean ± SEM. (n=3). Unpaired two-tailed Student’s t-test; ** p<0.01. B . Immunofluorescence experiments performed on HCT116 cells treated, or not, with oxaliplatin (0.5 μM) monitoring 53BP1 (grey). DAPI (blue) was used to stain DNA and the nuclei. Quantification of the staining is shown on the right side and is represented as the corrected nuclear fluorescence. Data are represented as the mean ± SEM. (n=3). Unpaired two-tailed Student’s t-test; *** p<0.001. C . Western blot analysis showing protein expression of TEAD4 and p53 family of proteins in HCT116 treated (Oxa), or not (NT) with oxaliplatin (0.5 μM). GAPDH was used as a loading control (n=3). D. Heat map corresponding to the genes differentially expressed in HCT116 cells after 24h of oxaliplatin treatment at IC50 (see Supplemental Table 1). The three replicates for the non-treated (NT) and treated (Oxa) are shown.

Article Snippet: Human HCT116 colorectal cancer cell line (ATCC 2017) was cultured in RPMI1640 supplemented with 10% FBS at 37°C in a humidified atmosphere with 5% CO2.

Techniques: Immunofluorescence, Staining, Fluorescence, Two Tailed Test, Western Blot, Expressing, Control

Journal: bioRxiv

Article Title: The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in HCT116 colon cancer cells

doi: 10.1101/2023.03.17.533075

Figure Lengend Snippet: A . Immunofluorescence experiments performed on HCT116 cells treated, or not, with oxaliplatin (0.5 μM) monitoring TEAD4 (top panels), YAP (middle panels), and TAZ (bottom panels) nuclear localization (red). DAPI (blue) was used to stain DNA and the nuclei. Quantification of both stainings are shown on the right side of the figures and are represented as the corrected nuclear fluorescence. Data are represented as the mean ± SEM (n=3). Unpaired two-tailed Student’s t-test; **** p < 0.0001. B . Western blot analysis showing protein expression and/or activation of Hippo pathway components in HCT116 cells treated (Oxa), or not (NT) with oxaliplatin (0.5 μM). GAPDH was used as a loading control (n=3). C . Western blot analysis after subcellular fractionation showing the relative amount of YAP and TAZ protein in the nuclear fraction of HCT116 cells treated (Oxa), or not (NT) with oxaliplatin (0.5 μM). Histone H3 was used as a nuclear loading control for the fractionation (n=3).

Article Snippet: Human HCT116 colorectal cancer cell line (ATCC 2017) was cultured in RPMI1640 supplemented with 10% FBS at 37°C in a humidified atmosphere with 5% CO2.

Techniques: Immunofluorescence, Staining, Fluorescence, Two Tailed Test, Western Blot, Expressing, Activation Assay, Control, Fractionation

Journal: bioRxiv

Article Title: The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in HCT116 colon cancer cells

doi: 10.1101/2023.03.17.533075

Figure Lengend Snippet: A . HCT116- shYAP and HCT116- shLuc cell lines were treated with increasing doses of oxaliplatin for 96h. Cell viability analysis was then assessed using SRB assay and the IC50 of oxaliplatin was calculated as the concentration needed to kill 50% of the cells (shown in the inset). Paired two-tailed Student’s t-test,* p<0.05. B . HCT116-shYAP-siTAZ and HCT116-shLuc-siCtl (control) cell lines were treated with increasing doses of oxaliplatin for 96h. Cell viability analysis was then assessed using SRB assay and the IC50 of oxaliplatin was calculated as the concentration needed to kill 50% of the cells (shown in the inset). Paired two-tailed Student’s t-test, ** p<0.01. C . Western blot analysis showing protein expression of TAZ and YAP in HCT116- shLuc , -siTAZ , -shYAP and both -shYAP-siTAZ used in panel A and B. Tubulin was used as a loading control (n=3). D . HCT116 cells were incubated with increasing concentrations of oxaliplatin and either Verteporfin or CA3. Cell viability was assessed with the SRB assay in 2D to obtain the viability matrix. Drug concentrations were as follows: Verteporfin (from 0.437 to 7 μM), CA3 (from 0.004 to 0.75 μM) and oxaliplatin (from 0.0185 to 1.2 μM). The synergy matrices were calculated as described in Materials and Methods.

Article Snippet: Human HCT116 colorectal cancer cell line (ATCC 2017) was cultured in RPMI1640 supplemented with 10% FBS at 37°C in a humidified atmosphere with 5% CO2.

Techniques: Sulforhodamine B Assay, Concentration Assay, Two Tailed Test, Control, Western Blot, Expressing, Incubation

Journal: bioRxiv

Article Title: The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in HCT116 colon cancer cells

doi: 10.1101/2023.03.17.533075

Figure Lengend Snippet: A . Western blot analysis showing protein expression of YAP and TAZ in HCT116 treated, or not, with oxaliplatin (0.5 μM) and/or Dasatinib (50 nM and 100 nM). Phopsho-SRC blotting was used to evaluate the inhibition of SRC activity using Dasatinib. GAPDH was used as a loading control (n=3). Quantification of the blots (performed using Image J software) is shown on the right side of the figure. B . Immunofluorescence experiments performed in HCT116 cells treated, or not, with oxaliplatin (0.5 μM) and/or Dasatinib (50 nM) monitoring YAP (top panels) and TAZ (bottom panels) nuclear localization (red). DAPI (blue) was used to stain DNA and the nuclei. Quantification of both stainings are shown on the right side of the figures and are represented as the corrected nuclear fluorescence. Data are represented as the mean ± SEM (n=3). Unpaired two-tailed Student’s t-test; ****p < 0.0001. C . HCT116 colorectal cancer cell lines were incubated with increasing concentrations of oxaliplatin and Dasatinib. Cell viability was assessed with the SRB assay in 2D to obtain the viability matrix. Drug concentrations were as follows: Dasatinib (from 1 to 16 μM) and oxaliplatin (from 0.0185 to 1.2 μM). The synergy matrix was calculated as described in Materials and Methods.

Article Snippet: Human HCT116 colorectal cancer cell line (ATCC 2017) was cultured in RPMI1640 supplemented with 10% FBS at 37°C in a humidified atmosphere with 5% CO2.

Techniques: Western Blot, Expressing, Inhibition, Activity Assay, Control, Software, Immunofluorescence, Staining, Fluorescence, Two Tailed Test, Incubation, Sulforhodamine B Assay

Journal: Cancer health disparities

Article Title: Enhancing African American Participation in Biospecimens: A Case in Point for Pancreatic Cancer

doi: 10.1158/1538-7755.DISP20-PO-236

Figure Lengend Snippet: Racial representation of biobanks from diseases of the pancreas.

Article Snippet: Electronic address and Cancer Genome Atlas Research, 2017 ) American Type Culture Collection Pancreas Cancer cell lines N/A 0 66 33 12 https://www.atcc.org/ Prodo Labs Pancreas 2011-2016 11.5 54.9 33.6 226 ( Scharp et al., 2019 ) NPOD 1 Pancreas 2007-2020 18.3 68.1 13.6 492 GWAS 2 Pancreas Cancer 1993-2014 33.3 19.1 47.6 691 ( Park et al., 2018 ; Signorello et al., 2010 ; Signorello et al., 2005 ) CHTN 3 Pancreas Cancer 2015-2020 8.3 88.9 2.8 36 Allegheny Hospital Pancreas 2013-2017 19.1 61.8 19.1 283 University of Miami Pancreas 2013-2017 19.5 54.9 25.6 195 Open in a separate window 1 Network for Pancreatic Organ Donors with Diabetes 2 Genome Wide Association Studies 3 Coorporative Human Tissue Network Racial representation of biobanks from diseases of the pancreas.

Techniques: